ANB 020

Drug Profile

ANB 020

Alternative Names: ANB020

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator AnaptysBio
  • Class Antiallergics; Antiasthmatics; Antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 receptor-like 1 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Peanut hypersensitivity
  • Phase I Asthma

Most Recent Events

  • 04 Mar 2017 Pharmacodynamics data from a clinical study in Peanut hypersensitivity released by AnaptysBio
  • 03 Mar 2017 Updated safety, pharmacodynamic and pharmacokinetic data presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
  • 14 Feb 2017 AnaptysBio plans a phase II trial for Eosinophilic asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top